LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Back to previous search Search history
Advanced search

Your last searches

  1. AU="Carlo Gambacorti-Passerini"
  2. AU="Mahjabeen, Faria"
  3. AU="Roberto Giovannoni"
  4. AU="Rajendra Damu Patil"
  5. AU="Santos-García, Irene"
  6. AU="Josiah Willock, Robina"
  7. AU="Ciacci, Joseph"
  8. AU="Barker, A"
  9. AU="Chris Baraloto"
  10. AU="Wagner, Lloyd"
  11. AU="Jandrić, Petar Hayes"

Search results

Result 1 - 10 of total 14

Search options

  1. Article ; Online: Analogies between COVID-19 and Preeclampsia

    Valentina Giardini / Carlo Gambacorti-Passerini / Marco Casati / Andrea Carrer / Patrizia Vergani

    International Journal of Translational Medicine, Vol 3, Iss 15, Pp 203-

    Focus on Therapies

    2023  Volume 216

    Abstract: Preeclampsia is an obstetric pathology with striking similarities to COVID-19. The renin-angiotensin system plays a key role in the pathogenesis of both diseases. This report reviews the pharmacological strategies that have been suggested for the ... ...

    Abstract Preeclampsia is an obstetric pathology with striking similarities to COVID-19. The renin-angiotensin system plays a key role in the pathogenesis of both diseases. This report reviews the pharmacological strategies that have been suggested for the prevention and treatment of preeclampsia and that are potentially useful also in the treatment of COVID-19. Of note, both pathologies have in common an Angiotensin II-mediated endothelial dysfunction secondary to an angiogenic imbalance, with effects on vasculature, coagulation, and inflammation. These considerations are drawn from cases of the initial SARS-CoV-2 primary infection and may not apply to more recent SARS-CoV-2 variants or infections after COVID vaccination. The treatment options discussed included albumin infusion, aspirin, corticosteroids, the monoclonal antibody eculizumab, hydroxychloroquine, low molecular weight heparin, magnesium, melatonin, metformin, nitric oxide, proton pump inhibitors, statins, therapeutic apheresis, and vitamin D.
    Keywords COVID-19 ; SARS-CoV-2 ; preeclampsia ; renin-angiotensin system ; angiogenic factors ; PlGF ; Computer applications to medicine. Medical informatics ; R858-859.7
    Subject code 610
    Language English
    Publishing date 2023-04-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib

    Ilaria Crespiatico / Elisa Bossi / Filippo Brioschi / Rocco Piazza / Luca Mologni / Carlo Gambacorti‐Passerini

    Clinical Case Reports, Vol 8, Iss 1, Pp 71-

    Case report and biological characterization

    2020  Volume 74

    Abstract: Abstract Leu387Trp mutation, aroused in an imatinib‐non‐responsive CML patient, was selected by imatinib treatment along with other unknown factors responsible for resistance, and then it was overcome by bosutinib. These results will be useful for ... ...

    Abstract Abstract Leu387Trp mutation, aroused in an imatinib‐non‐responsive CML patient, was selected by imatinib treatment along with other unknown factors responsible for resistance, and then it was overcome by bosutinib. These results will be useful for treating patients with this rare mutation and will advise against automatically considering a new mutation as the cause of TKI resistance.
    Keywords chronic myeloid leukemia ; genetics ; hematology ; resistance ; TKI ; Medicine ; R ; Medicine (General) ; R5-920
    Language English
    Publishing date 2020-01-01T00:00:00Z
    Publisher Wiley
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling

    Monica Ceccon / Mario Mauri / Luca Massimino / Giovanni Giudici / Rocco Piazza / Carlo Gambacorti-Passerini / Luca Mologni

    Cancers, Vol 10, Iss 12, p

    2018  Volume 509

    Abstract: Targeted therapy is an effective, rational, and safe approach to solid and hematological tumors treatment. Unfortunately, a significant fraction of patients treated with tyrosine kinase inhibitors (TKI) relapses mainly because of gene amplification, ... ...

    Abstract Targeted therapy is an effective, rational, and safe approach to solid and hematological tumors treatment. Unfortunately, a significant fraction of patients treated with tyrosine kinase inhibitors (TKI) relapses mainly because of gene amplification, mutations, or other bypass mechanisms. Recently a growing number of papers showed how, in some cases, resistance due to oncogene overexpression may be associated with drug addiction: cells able to proliferate in the presence of high TKI doses become also TKI dependent, undergoing cellular stress, and apoptosis/death upon drug withdrawal. Notably, if a sub-cellular population survives TKI discontinuation it is also partially re-sensitized to the same drug. Thus, it is possible that a subset of patients relapsing upon TKI treatment may benefit from a discontinuous therapeutic schedule. We focused on two different hematologic malignancies, chronic myeloid leukemia (CML) and anaplastic large cell lymphoma (ALCL), both successfully treatable with TKIs. The two models utilized (LAMA and SUP-M2) differed in having oncogene overexpression as the sole cause of drug resistance (CML), or additionally carrying kinase domain mutations (ALCL). In both cases drug withdrawal caused a sudden overload of oncogenic signal, enhanced mitochondria activity, induced the release of a high amount of reactive oxygen species (ROS), and caused genotoxic stress and massive cell death. In LAMA cells (CML) we could rescue the cells from death by partially blocking downstream oncogenic signaling or lowering ROS detrimental effect by adding reduced glutathione.
    Keywords cancer ; oncogene ; inhibitors ; personalized medicine ; targeted therapy ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282
    Language English
    Publishing date 2018-12-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients

    Francesca Colombo / Giulia Pintarelli / Antonella Galvan / Sara Noci / Oscar Corli / Frank Skorpen / Pål Klepstad / Stein Kaasa / Alessandra Pigni / Cinzia Brunelli / Anna Roberto / Rocco Piazza / Alessandra Pirola / Carlo Gambacorti-Passerini / Augusto Tommaso Caraceni

    Scientific Reports, Vol 10, Iss 1, Pp 1-

    2020  Volume 8

    Abstract: Abstract Nausea and vomiting are often associated with opioid analgesia in cancer patients; however, only a subset of patients develop such side effects. Here, we tested the hypothesis that the occurrence of nausea and vomiting is modulated by the ... ...

    Abstract Abstract Nausea and vomiting are often associated with opioid analgesia in cancer patients; however, only a subset of patients develop such side effects. Here, we tested the hypothesis that the occurrence of nausea and vomiting is modulated by the genetic background of the patients. Whole exome sequencing of DNA pools from patients with either low (n = 937) or high (n = 557) nausea and vomiting intensity, recruited in the European Pharmacogenetic Opioid Study, revealed a preliminary association of 53 polymorphisms. PCR-based genotyping of 45 of these polymorphisms in the individual patients of the same series confirmed the association for six SNPs in AIM1L, CLCC1, MUC16, PDE3A, POM121L2, and ZNF165 genes. Genotyping of the same 45 polymorphisms in 264 patients of the Italian CERP study, also treated with opioids for cancer pain, instead confirmed the association for two SNPs in ZNF568 and PDE3A genes. Only one SNP, rs12305038 in PDE3A, was confirmed in both series, although with opposite effects of the minor allele on the investigated phenotype. Overall, our findings suggest that genetic factors are indeed associated with nausea and vomiting in opioid-treated cancer patients, but the role of individual polymorphisms may be weak.
    Keywords Medicine ; R ; Science ; Q
    Subject code 616
    Language English
    Publishing date 2020-01-01T00:00:00Z
    Publisher Nature Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells.

    Luca Mologni / Stefania Brussolo / Monica Ceccon / Carlo Gambacorti-Passerini

    PLoS ONE, Vol 7, Iss 12, p e

    2012  Volume 51449

    Abstract: Activation of Wnt signalling due to inability to degrade β-catenin is found in >85% of colorectal cancers. Approximately half of colon cancers express a constitutively active KRAS protein. A significant fraction of patients show both abnormalities. We ... ...

    Abstract Activation of Wnt signalling due to inability to degrade β-catenin is found in >85% of colorectal cancers. Approximately half of colon cancers express a constitutively active KRAS protein. A significant fraction of patients show both abnormalities. We previously reported that simultaneous down-regulation of both β-catenin and KRAS was necessary to induce significant cell death and tumor growth inhibition of colorectal cancer cells. Although attractive, an RNAi-based therapeutic approach is still far from being employed in the clinical setting. Therefore, we sought to recapitulate our previous findings by the use of small-molecule inhibitors of β-catenin and KRAS. We show here that the β-catenin inhibitors PKF115-584 and pyrvinium pamoate block β-catenin-dependent transcriptional activity and synergize with the KRAS inhibitor S-trans, trans-farnesylthiosalicylic acid (FTS, salirasib) in colon cancer cells driven by Wnt and KRAS oncogenic signals, but not in cells carrying BRAF mutations. The combined use of these compounds was superior to the use of any drug alone in inducing cell growth arrest, cell death, MYC and survivin down-modulation, and inhibition of anchorage-independent growth. Expression analysis of selected cancer-relevant genes revealed down-regulation of CD44 as a common response to the combined treatments. These data provide a proof of principle for a combination therapeutic strategy in colorectal cancer.
    Keywords Medicine ; R ; Science ; Q
    Subject code 610
    Language English
    Publishing date 2012-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV

    Amber Yasmeen / Amal Alachkar / Hafedh Dekhil / Carlo Gambacorti-Passerini / Ala-Eddin Al Moustafa

    Journal of Oncology, Vol

    2010  Volume 2010

    Keywords Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Oncology ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Language English
    Publishing date 2010-01-01T00:00:00Z
    Publisher Hindawi Publishing Corporation
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients

    Giovanni Caocci / Marianna Greco / Giuseppe Delogu / Christian Secchi / Bruno Martino / Claudia Labate / Elisabetta Abruzzese / Malgorzata Monika Trawinska / Sara Galimberti / Federica Orru / Claudio Fozza / Carlo Gambacorti Passerini / Francesco Galimi / Giorgio La Nasa

    Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-

    2016  Volume 3

    Abstract: Abstract We studied telomere length in 32 CML patients who discontinued imatinib after achieving complete molecular remission and 32 age-sex-matched controls. The relative telomere length (RTL) was determined by q-PCR as the telomere to single copy gene ( ...

    Abstract Abstract We studied telomere length in 32 CML patients who discontinued imatinib after achieving complete molecular remission and 32 age-sex-matched controls. The relative telomere length (RTL) was determined by q-PCR as the telomere to single copy gene (36B4) ratio normalized to a reference sample (K-562 DNA). Age-corrected RTL (acRTL) was also obtained. The 36-month probability of treatment-free remission (TFR) was 59.4 %. TFR patients showed shorter acRTL compared to relapsed (mean ± SD = 0.01 ± 0.14 vs 0.20 ± 0.21; p = 0.01). TFR was significantly higher in CML patients with acRTL ≤0.09 (78.9 vs 30.8 %, p = 0.002). CML stem cells harboring longer telomeres possibly maintain a proliferative potential after treatment discontinuation.
    Keywords Chronic myeloid leukemia ; Telomere ; Treatment-free remission ; Imatinib ; Telomerase ; Diseases of the blood and blood-forming organs ; RC633-647.5 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282
    Language English
    Publishing date 2016-07-01T00:00:00Z
    Publisher BioMed Central
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

    Matteo Dragani / Giovanna Rege Cambrin / Paola Berchialla / Irene Dogliotti / Gianantonio Rosti / Fausto Castagnetti / Isabella Capodanno / Bruno Martino / Marco Cerrano / Dario Ferrero / Carlo Gambacorti-Passerini / Monica Crugnola / Chiara Elena / Massimo Breccia / Alessandra Iurlo / Daniele Cattaneo / Sara Galimberti / Antonella Gozzini / Monica Bocchia /
    Francesca Lunghi / Michele Cedrone / Nicola Sgherza / Luigia Luciano / Sabina Russo / Marco Santoro / Valentina Giai / Giovanni Caocci / Luciano Levato / Elisabetta Abruzzese / Federica Sora / Giuseppe Saglio / Carmen Fava

    Journal of Clinical Medicine, Vol 9, Iss 3692, p

    2020  Volume 3692

    Abstract: Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We ... ...

    Abstract Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported—281 chronic-phase CML patients were included in this subanalysis. Median follow-up since discontinuation was 2 years. Overall, 2203 analyses were performed, 17.9% in the first three months and 38.4% in the first six months. Eighty-six patients lost major molecular response (MMR) in a mean time of 5.7 months—65 pts (75.6%) during the first six months. We evaluated the number of patients who would experience a delay in diagnosis of MMR loss if a three-month monitoring schedule was adopted. In the first 6 months, 19 pts (29.2%) would have a one-month delay, 26 (40%) a 2-month delay. Very few patients would experience a delay in the following months. A less intense frequency of monitoring, particularly after the first 6 months off treatment, would not have affected the success of treatment-free remission (TFR) nor put patients at risk of progression.
    Keywords chronic myeloid leukemia ; treatment-free remission ; molecular monitoring ; Medicine ; R
    Subject code 610 ; 616
    Language English
    Publishing date 2020-11-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine

    Diletta Fontana / Mario Mauri / Rossella Renso / Mattia Docci / Ilaria Crespiatico / Lisa M. Røst / Mi Jang / Antonio Niro / Deborah D’Aliberti / Luca Massimino / Mayla Bertagna / Giovanni Zambrotta / Mario Bossi / Stefania Citterio / Barbara Crescenzi / Francesca Fanelli / Valeria Cassina / Roberta Corti / Domenico Salerno /
    Luca Nardo / Clizia Chinello / Francesco Mantegazza / Cristina Mecucci / Fulvio Magni / Guido Cavaletti / Per Bruheim / Delphine Rea / Steen Larsen / Carlo Gambacorti-Passerini / Rocco Piazza

    Nature Communications, Vol 11, Iss 1, Pp 1-

    2020  Volume 16

    Abstract: ETNK1 mutations are recurrent in leukemia but how they contribute to oncogenesis is still unclear. Here, the authors show that ETNK1 mutations increase mitochondrial activity, ROS and H2AX levels and that these effects can be rescued upon ... ...

    Abstract ETNK1 mutations are recurrent in leukemia but how they contribute to oncogenesis is still unclear. Here, the authors show that ETNK1 mutations increase mitochondrial activity, ROS and H2AX levels and that these effects can be rescued upon phosphoethanolamine supplementation.
    Keywords Science ; Q
    Language English
    Publishing date 2020-11-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub

    Rocco Piazza / Vera Magistroni / Sara Redaelli / Mario Mauri / Luca Massimino / Alessandro Sessa / Marco Peronaci / Maciej Lalowski / Rabah Soliymani / Caterina Mezzatesta / Alessandra Pirola / Federica Banfi / Alicia Rubio / Delphine Rea / Fabio Stagno / Emilio Usala / Bruno Martino / Leonardo Campiotti / Michele Merli /
    Francesco Passamonti / Francesco Onida / Alessandro Morotti / Francesca Pavesi / Marco Bregni / Vania Broccoli / Marc Baumann / Carlo Gambacorti-Passerini

    Nature Communications, Vol 9, Iss 1, Pp 1-

    2018  Volume 13

    Abstract: SETBP1 variants occur as somatic mutations in several malignancies and as de novo germline mutations in developmental disorders. Here the authors provide evidence that SETBP1 binds to gDNA in AT-rich promoter regions to promote target gene upregulation, ... ...

    Abstract SETBP1 variants occur as somatic mutations in several malignancies and as de novo germline mutations in developmental disorders. Here the authors provide evidence that SETBP1 binds to gDNA in AT-rich promoter regions to promote target gene upregulation, indicating SETBP1 functions directly to regulate transcription.
    Keywords Science ; Q
    Language English
    Publishing date 2018-06-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top